Basic Stats
| LEI | 529900TDZZOKI5EBQ513 |
| CIK | 1305773 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Conformis Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37474 Conformis, Inc. (Exact name of registrant as specified in its char |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CONFORMIS, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONFORMIS, INC. FIRST: The name of the corporation is Conformis, Inc. (the “Corporation”). SECOND: The addr ess of the Corpor ation' s registered office in the State of Delaware is 1209 Orange Street, Corporation Trust Center, Wilmington, Delaware 19801, New Castle County. The name of the Corporation's registered agent at such addres |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
Exhibit 3.2 CONFORMIS, INC. (THE “CORPORATION”) SECOND AMENDED AND RESTATED BYLAWS ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Time and Place of Meetings. All meetings of the stockholders for the election of directors or for any other purpose shall be held at such time and place, within or without the State of Delaware, as may be designated by the Board of Directors, or by the Chairman of the Bo |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| September 5, 2023 |
As filed with the Securities and Exchange Commission on September 5, 2023 As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. |
|
| August 31, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 2, 2023 |
Warrant Exchange Agreement This Warrant Exchange Agreement (the “Agreement”) is made and entered into as of June 22, 2023, by and between Conformis, Inc. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, |
|
| August 2, 2023 |
Conformis Reports Second Quarter 2023 Financial Results Conformis Reports Second Quarter 2023 Financial Results BILLERICA, Mass., August 2, 2023 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary •Total revenue of $13.0 million, a decrease of 15% year- |
|
| August 2, 2023 |
SETTLEMENT AND LICENSE AGREEMENT This Settlement and License Agreement (“Agreement”) is entered into as of the Effective Date by and between Osteoplastics, LLC (“Osteoplastics”), on the one hand, and Conformis, Inc. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| July 24, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 14, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Conformis, Inc. |
|
| July 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| June 23, 2023 |
AGREEMENT AND PLAN OF MERGER among: CONFORMIS, INC, a Delaware corporation; RESTOR3D, INC. |
|
| June 23, 2023 |
Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2. |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 19, 2023 |
CONFORMIS, INC. CONSULTING AGREEMENT CONFORMIS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”), dated May 18, 2023 but effective as of June 10, 2023 (the “Effective Date”), is by and between Conformis, Inc., a Delaware corporation (the “Company”), and Robert S. Howe, an individual with an address listed on the signature page hereto (the “Consultant”). WHEREAS, the Company desires consulting and similar service |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 8, 2023 |
Conformis Reports First Quarter 2023 Financial Results Conformis Reports First Quarter 2023 Financial Results BILLERICA, Mass., May 8, 2023 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary •Total revenue of $12.8 million, a decrease of 17% year-over- |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis |
|
| March 24, 2023 |
proxy statement for the 2023 Annual Meeting TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| March 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| March 1, 2023 |
FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 1st day of August, 2022, by and among CONFORMIS, INC. |
|
| March 1, 2023 |
Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results BILLERICA, Mass., March 1, 2023 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary •Total revenue of $17.4 mi |
|
| March 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, Inc |
|
| March 1, 2023 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 1, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Conformis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.00001 |
|
| March 1, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Conformis Cares LLC Delaware ConforMIS Europe GmbH Germany ConforMIS Hong Kong Limited Hong Kong Conformis India LLP India ConforMIS UK Limited United Kingdom ImaTX, Inc. California |
|
| February 14, 2023 |
US20717E2000 / CONFORMIS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-cfms123122a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Conformis, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 20717E200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2023 |
US20717E2000 / CONFORMIS INC / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Conformis, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 20717E200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 10, 2023 |
Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022 Company Launches New Advertising Campaign BILLERICA, Mass. |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 9, 2022 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF CONFORMIS, INC. |
|
| November 9, 2022 |
Conformis, Inc. Effects 1-for-25 Reverse Stock Split Conformis, Inc. Effects 1-for-25 Reverse Stock Split BILLERICA, Mass., November 9, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) (“Conformis”) announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with the opening of trading on November 10, 2022, Conformis’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 2, 2022 |
Conformis Reports Third Quarter 2022 Financial Results Conformis Reports Third Quarter 2022 Financial Results BILLERICA, Mass., November 2, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Summary •Total revenue of $13.8 million, a decrease of 3% ye |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Confo |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 16, 2022 |
proxy statement for the Special Meeting TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| September 2, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| August 8, 2022 |
Conformis Reports Second Quarter 2022 Financial Results Conformis Reports Second Quarter 2022 Financial Results BILLERICA, Mass., August 8, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Summary •Total revenue of $15.3 million. Total revenue in the se |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, |
|
| July 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 9, 2022 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis |
|
| May 4, 2022 |
Conformis Reports First Quarter 2022 Financial Results Conformis Reports First Quarter 2022 Financial Results BILLERICA, Mass., May 4, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 Summary ?Total revenue of $15.6 million, an increase of 12% year-over |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| April 1, 2022 |
Registration No. 333- As filed with the Securities and Exchange Commission on April 1, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| April 1, 2022 |
Conformis, Inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of March 21, 2022 (the ?Effective Date?) by and between Conformis, Inc., a Delaware corporation (the ?Company?), and Michael Fillion, an individual residing at 6 Butler Drive, Middleton, MA 01949 (the ?Executive?). BACKGROUND A.The Company desires to retain the services of the Executive as |
|
| April 1, 2022 |
CONFORMIS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Inducement Grant Conformis, Inc. (the ?Company?) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Michael Fillion Grant Date: April 1, 2022 Number of shares of the Company?s Common Stock subject to this option (?Shares?): 425,000 Option |
|
| April 1, 2022 |
CONFORMIS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Conformis, Inc. (the ?Company?) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Michael Fillion Grant Date: April 1, 2022 Number of Restricted Stock Units (?RSUs?) granted: 425,000 Vesting Start Date: April 1, 2 |
|
| April 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Conformis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.00001 |
|
| March 23, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definit |
|
| March 23, 2022 |
proxy statement for the 2022 Annual Meeting of Stockholders TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 14, 2022 |
Conformis, Inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of February 28, 2022 (the ?Effective Date?) by and between Conformis, Inc., a Delaware corporation (the ?Company?), and Denise Pedulla, an individual residing at 60C Seven Springs Lane, Burlington, MA 01830 (the ?Executive?). BACKGROUND A.The Company desires to retain the services of the Ex |
|
| March 14, 2022 |
CONFORMIS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Conformis, Inc. (the ?Company?) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Denise Pedulla Grant Date: March 14, 2022 Number of Restricted Stock Units (?RSUs?) granted: 450,000 Vesting Start Date: March 14, |
|
| March 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Conformis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.00001 |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| March 14, 2022 |
Inducement Non-Statutory Stock Option Agreement for Denise Pedulla CONFORMIS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Inducement Grant Conformis, Inc. (the ?Company?) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Denise Pedulla Grant Date: March 14, 2022 Number of shares of the Company?s Common Stock subject to this option (?Shares?): 450,000 Option |
|
| March 14, 2022 |
nducement Restricted Stock Unit Award for Denise Pedulla CONFORMIS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Conformis, Inc. (the ?Company?) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Denise Pedulla Grant Date: March 14, 2022 Number of Restricted Stock Units (?RSUs?) granted: 450,000 Vesting Start Date: March 14, |
|
| March 14, 2022 |
CONFORMIS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Inducement Grant Conformis, Inc. (the ?Company?) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Denise Pedulla Grant Date: March 14, 2022 Number of shares of the Company?s Common Stock subject to this option (?Shares?): 450,000 Option |
|
| March 14, 2022 |
Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary BILLERICA, Mass., Mar. 14, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. ?We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong pub |
|
| March 14, 2022 |
Employment Agreement, dated February 28, 2022, between Conformis, Inc. and Denise Pedulla Conformis, Inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of February 28, 2022 (the ?Effective Date?) by and between Conformis, Inc., a Delaware corporation (the ?Company?), and Denise Pedulla, an individual residing at 60C Seven Springs Lane, Burlington, MA 01830 (the ?Executive?). BACKGROUND A.The Company desires to retain the services of the Ex |
|
| March 14, 2022 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 14, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| March 11, 2022 |
Gary Fischetti nominated to join Conformis’ Board of Directors Gary Fischetti nominated to join Conformis? Board of Directors BILLERICA, Mass., March 11, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), announced today that Gary P. Fischetti has been nominated to stand for election to the Company?s Board of Directors at the Company?s 2022 Annual Meeting of Stockholders, scheduled to be held on May 4, 2022. Mr. Fischetti will replace Richard Meelia, who |
|
| March 11, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 2, 2022 |
Conformis, Inc. Reports Fourth Quarter and Year End 2021 Financial Results Conformis, Inc. Reports Fourth Quarter and Year End 2021 Financial Results BILLERICA, Mass., March 2, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Summary ?Finalized commercial laun |
|
| March 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| March 2, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Conformis Cares LLC Delaware ConforMIS Europe GmbH Germany ConforMIS Hong Kong Limited Hong Kong Conformis India LLP India ConforMIS UK Limited United Kingdom ImaTX, Inc. California |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, Inc |
|
| March 2, 2022 |
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 1, 2021, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, ?Collateral Agent?), and CONFORMIS, INC. |
|
| March 2, 2022 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 2, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| March 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Conformis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.00001 |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.00001 per share, of Conformis, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 15, 2022 |
CFMS / ConforMIS Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
CFMS / ConforMIS Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Conformis, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 20717E101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 9, 2022 |
CFMS / ConforMIS Inc / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 6, 2022 |
Conformis, Inc. Provides Business Update and Initial Expectations for 2022 Company Launches Innovative Image-to-Implant? Platinum Services? Program to Better Serve Patients and Surgeons BILLERICA, Mass., January 6, 2022 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, today announced preliminary re |
|
| January 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| January 4, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 23, 2021 |
Conformis, Inc. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?), dated December 22, 2021 but effective as of January 17, 2021 (the ?Effective Date?), is by and between Conformis, Inc., a Delaware corporation (the ?Company?), and J. Brent Alldredge, an individual with an address listed on the signature page hereto (the ?Consultant?). WHEREAS, the Company desires consulting and sim |
|
| December 23, 2021 |
Conformis, Inc. Announces Departure of Chief Legal Officer, Corporate Secretary Conformis, Inc. Announces Departure of Chief Legal Officer, Corporate Secretary BILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022 to become the General Counsel at Bruker Corporation, a global, publicly t |
|
| November 23, 2021 |
CREDIT AND SECURITY AGREEMENT (TERM LOAN) dated as of November 22, 2021 by and among CONFORMIS, INC. |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 9, 2021 |
Opinion of Hogan Lovells US LLP Registration No. 333- As filed with the Securities and Exchange Commission on November 8, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employ |
|
| November 3, 2021 |
Conformis Reports Third Quarter 2021 Financial Results Conformis Reports Third Quarter 2021 Financial Results BILLERICA, Mass., November 3, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Summary ?Total revenue of $14.3 million, a decrease of 12% y |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Confo |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| September 20, 2021 |
Conformis, Inc. Provides Business Update Business Update Provided in Advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit BILLERICA, Mass., September 20, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) provided today an update of its third quarter revenue performance expectations in advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (?OpCo Summit?) |
|
| August 4, 2021 |
Conformis Reports Second Quarter 2021 Financial Results EX-99.1 2 ex-991cfmsx063021earnings.htm EX-99.1 Conformis Reports Second Quarter 2021 Financial Results BILLERICA, Mass., August 4, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Summary •Total r |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 4, 2021 |
\\DC - 088353/000017 - 16216426 v8 CONFORMIS, INC. 2015 STOCK INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Conformis, Inc., a Delaware corporation (the ?Company?), hereby grants performance- based restricted stock units (the ?Performance Stock Units?) relating to shares of the Company?s common stock, par value $0.0001 per share (the ?Stock?), to the Grantee named be |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Conformis, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 20717E101 (CUSIP Number) June 8, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| June 4, 2021 |
Registration No. 333- As filed with the Securities and Exchange Commission on June 4, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer I |
|
| May 27, 2021 |
EXHIBIT 10.1 CONFORMIS, INC. 2015 STOCK INCENTIVE PLAN AS AMENDED BY THE FIRST AMENDMENT approved by Conformis, Inc. Stockholders on May 24, 2021 (Reflects one-for-two reverse stock split of Conformis? common stock that became effective on June 16, 2015) 1.Purpose The purpose of this 2015 Stock Incentive Plan (the ?Plan?) of Conformis, Inc., a Delaware corporation (the ?Company?), is to advance th |
|
| May 27, 2021 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF CONFORMIS, INC. Conformis, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the DGCL?), does hereby certify as follows: FIRST: The name of the Corporation is Conformis, Inc., the date of filing of its Restated Certificate |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 7, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 5, 2021 |
Conformis Reports First Quarter 2021 Financial Results Conformis Reports First Quarter 2021 Financial Results BILLERICA, Mass., May 5, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2021. First Quarter 2021 Summary ?Total revenue of $13.8 million, a decrease of 16% year-over- |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis |
|
| April 22, 2021 |
Conformis Announces License Agreement with Paragon 28 Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand BILLERICA, Mass. |
|
| April 22, 2021 |
Conformis Announces Achievement of Third Milestone Under Development and License Agreements Conformis Announces Achievement of Third Milestone Under Development and License Agreements BILLERICA, Mass. |
|
| April 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definit |
|
| April 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definit |
|
| March 30, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definit |
|
| March 4, 2021 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 4, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, Inc |
|
| March 4, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Conformis Cares LLC Delaware ConforMIS Europe GmbH Germany ConforMIS Hong Kong Limited Hong Kong Conformis India LLP India ConforMIS UK Limited United Kingdom ImaTX, Inc. California |
|
| March 4, 2021 |
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 1, 2021, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, ?Collateral Agent?), and CONFORMIS, INC. |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| March 3, 2021 |
Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results BILLERICA, Mass., March 3, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the fourth quarter and year ended December 31, 2020. Fourth Quarter 2020 Summary •Total revenue of $16.7 million, a decrease of 16% year-over-year on a reported basis and 17% on a constant currency basis. • |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 Conformis, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37474 56-2463152 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| February 17, 2021 |
Conformis, Inc. Announces Pricing of $85 Million Underwritten Offering of Common Stock Exhibit 99.1 Conformis, Inc. Announces Pricing of $85 Million Underwritten Offering of Common Stock BILLERICA, Mass., February 12, 2021 (GLOBE NEWSWIRE) - Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering price of $1.05 per share. The gross proceeds from the offering will be approximately $85 million |
|
| February 17, 2021 |
Exhibit 1.1 EXECUTION VERSION 80,952,381 Shares Conformis, Inc. Common Stock UNDERWRITING AGREEMENT February 12, 2021 Oppenheimer & Co. Inc. as Representative of the several Underwriters named in Schedule I hereto 85 Broad Street New York, NY 10004 Ladies and Gentlemen: Conformis, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions contained herein, to sell |
|
| February 16, 2021 |
80,952,381 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-237351 Prospectus Supplement (to Prospectus dated August 5, 2020) 80,952,381 Shares of Common Stock We are offering 80,952,381 shares of our common stock, $0.00001 par value per share, at a purchase price of $1.05 per share pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 11, 2021 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-237351 The information contained in this preliminary prospectus supplement is not complete and may be changed. Subject to Completion, dated February 11, 2021 Preliminary Prospectus Supplement (to Prospectus dated August 5, 2020) Shares of Common Stock We are offering shares of our common stock, $0.00001 par value per |
|
| December 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 5, 2020 |
Registration No. 333- As filed with the Securities and Exchange Commission on November 5, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employ |
|
| November 4, 2020 |
Form of Global Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan Form of Global Nonstatutory Stock Option Agreement CONFORMIS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Conformis, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2015 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Date of this option grant: Number of shares of the Company’s C |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Confo |
|
| November 4, 2020 |
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of August 20, 2020, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and CONFORMIS, INC. |
|
| November 4, 2020 |
Conformis Reports Third Quarter 2020 Financial Results Conformis Reports Third Quarter 2020 Financial Results BILLERICA, Mass., November 4, 2020 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Summary • Total revenue of $16.1 million, a decrease of 7% year-over-year on a reported and constant currency basis. • Product revenue of $16.0 million, a decre |
|
| October 6, 2020 |
Conformis Reports Preliminary Third Quarter Revenue Results Earnings Call to be Hosted on November 4, 2020 BILLERICA, Mass. |
|
| October 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| October 5, 2020 |
CFMS / ConforMIS, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 25, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-237351 Prospectus Supplement (to Prospectus dated August 5, 2020) 18,005,041 Units, Each Consisting of One Share of Common Stock (or One Pre-Funded Warrant in lieu thereof) and One Warrant to Purchase One Share of Common Stock We are offering (i) 8,512,088 units at a purchase price of $0.9581 per unit consisting of one share |
|
| September 24, 2020 |
Execution Version COMMON STOCK PURCHASE WARRANT CONFORMIS, INC. Warrant Shares: 18,005,041 Initial Exercise Date: September 28, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial E |
|
| September 24, 2020 |
Conformis, Inc. Announces $17.25 Million Registered Direct Offering Priced At-The-Market Conformis, Inc. Announces $17.25 Million Registered Direct Offering Priced At-The-Market BILLERICA, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) - Conformis, Inc. (Nasdaq: CFMS) today announced it has entered into a definitive agreement with a healthcare focused institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 8,512,088 shares o |
|
| September 24, 2020 |
Form of Subscription Agreement EXECUTION VERSION Conformis, Inc. 600 Technology Park Drive, 4th Floor Billerica, MA 01821 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with Conformis, Inc., a Delaware corporation (the “Company”) as follows: 1.This Subscription Agreement, including the Terms and Conditions For Purchase of Securities attached hereto as Annex I (collectively, (this “Agreement |
|
| September 24, 2020 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT CONFORMIS, INC. Warrant Shares: 9,492,953 Issuance Date/Initial Exercise Date: September 28, 2020 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| September 24, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| September 24, 2020 |
Execution Version CONFORMIS, INC. 18,005,041 Units, Each Consisting of One Share of Common Stock (or Pre-Funded Warrants in lieu thereof) and a Warrant to Purchase One Share of Common Stock PLACEMENT AGENT AGREEMENT September 23, 2020 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”) Conformis, Inc., |
|
| August 6, 2020 |
Up to $17,555,700 of Shares of Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| August 6, 2020 |
Prospectus Supplement (To Prospectus dated August 5, 2020) Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| August 6, 2020 |
Registration No. 333- As filed with the Securities and Exchange Commission on August 5, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 5, 2020 |
Conformis Reports Second Quarter 2020 Financial Results and Announces Planned Portfolio Expansion Targeted at Ambulatory Surgical Centers BILLERICA, Mass. |
|
| August 5, 2020 |
Sales Agreement, dated August 5, 2020, by and between Conformis, Inc. and Cowen and Company, LLC CONFORMIS, INC. $25,000,000 SALES AGREEMENT August 5, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Conformis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement |
|
| August 5, 2020 |
Form of Global Restricted Stock Agreement CONFORMIS, INC. RESTRICTED STOCK AGREEMENT Conformis, Inc. (the “Company”) has selected you to receive the following restricted stock award, which is subject to the provisions of the Company’s 2015 Stock Incentive Plan (the “Plan”) and the terms and conditions contained in this Restricted Stock Agreement. Name of Recipient: Number of shares of restricted c |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, |
|
| August 3, 2020 |
August 3, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 6, 2020 |
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 1, 2020, effective as of June 30, 2020, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and CONFORMIS, INC. |
|
| July 6, 2020 |
Conformis Reports Preliminary Second Quarter Revenue Results, Amendment to Credit Agreement Earnings Call to be Hosted on August 5, 2020 BILLERICA, Mass. |
|
| July 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 28, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 28, 2020 |
Conformis Announces Settlement of Patent Dispute Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants BILLERICA, Mass. |
|
| May 28, 2020 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis |
|
| May 11, 2020 |
Conformis Reports First Quarter 2020 Financial Results Conformis Reports First Quarter 2020 Financial Results BILLERICA, Mass., May 11, 2020 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific joint replacement implants designed to fit each patient's unique anatomy, announced today financial results for the |
|
| May 11, 2020 |
EX-10.2 3 cfms033120-ex102xinnovatu.htm EXHIBIT 10.2 CONSENT UNDER LOAN AND SECURITY AGREEMENT THIS CONSENT under Loan and Security Agreement (this “Consent”) is entered into as of April 17, 2020, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agen |
|
| May 11, 2020 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered as of March 1, 2020 and effective as of December 1, 2019, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), EAST WEST BANK in its capacity as a Lender (“Bank”), and CONFORMIS, INC. |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 30, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 20, 2020 |
Promissory Note, dated as of April 9, 2020 Borrower: Conformis, Inc. Lender: East West Bank Loan Servicing Department 9300 Flair Drive, 6th Floor El Monte, CA 91731 Principal Amount: $4,719,800.00 Date of Note: April 9, 2020 PROMISSORY NOTE PROMISE TO PAY. The borrower identified above (“Borrower”) promises to pay to East West Bank ("Lender"), or order, in lawful money of the United States of America, the principal amount specified above w |
|
| April 17, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 9, 2020 |
CFMS / ConforMIS, Inc. DEFA14A - - DEFA14A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| March 23, 2020 |
Form S-3 (Registration No. 333-237351) Use these links to rapidly review the document Table of Contents Table of Contents As filed with the Securities and Exchange Commission on March 23, 2020 Registration No. |
|
| March 23, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| March 23, 2020 |
Withdraws Previous 2020 Growth Outlook Conformis Announces Actions to Mitigate COVID-19 Impact Withdraws Previous 2020 Growth Outlook • Implementing furlough of approximately 1/3 of its direct workforce and substantially all of its temporary workforce • Furloughed employees will be immediately eligible for unemployment benefits and will maintain their existing healthcare coverage through Conformis • Continuing to produce backlog orders and new orders; Interruptions in supply chain are not currently anticipated • Continuing to progress new product development programs BILLERICA, Mass. |
|
| March 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| March 13, 2020 |
CFMS / ConforMIS, Inc. DEFA14A - - DEFA14A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definit |
|
| March 13, 2020 |
TABLE OF CONTENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy S |
|
| March 5, 2020 |
Exhibit 99.2 CORPORATE PARTICIPANTS Mark A. Augusti Conformis, Inc. - CEO, President & Director Robert S Howe Conformis, Inc. - CFO & Treasurer CONFERENCE CALL PARTICIPANTS Kyle William Rose Canaccord Genuity Corp., Research Division - Senior Analyst Lilia-Celine Breton Lozada JP Morgan Chase & Co, Research Division - Research Analyst Ryan Benjamin Zimmerman BTIG, LLC, Research Division - Director |
|
| March 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2020 |
EXHIBIT 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock, par value $0.00001 per share (the “common stock”), of Conformis, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act” |
|
| March 3, 2020 |
FOURTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Fourth Amendment to Amended and Restated Employment Agreement (“Amendment”), entered into as of November 2, 2019 (“Amendment Effective Date”), is by and between Conformis, Inc. |
|
| March 3, 2020 |
Conformis Reports Fourth Quarter and Year End 2019 Financial Results Conformis Reports Fourth Quarter and Year End 2019 Financial Results BILLERICA, Mass. |
|
| March 3, 2020 |
FIFTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Fifth Amendment to Amended and Restated Employment Agreement (“Amendment”), entered into as of February 5, 2020 (“Amendment Effective Date”), is by and between Conformis, Inc. |
|
| March 3, 2020 |
CONFORMIS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Inducement Grant Conformis, Inc. (the “Company”) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shares”): Option exercise price per Share: $ Vesting S |
|
| March 3, 2020 |
CONFORMIS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Conformis, Inc. (the “Company”) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of Restricted Stock Units (“RSUs”) granted: Vesting Start Date: Vesting Schedule: []% of the RSUs []% of the RSU |
|
| March 3, 2020 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (“Amendment”), entered into as of December 23, 2019 (“Amendment Effective Date”), is by and between Conformis, Inc. |
|
| March 3, 2020 |
Form of Inducement Incentive Grant Agreement CONFORMIS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Inducement Grant Conformis, Inc. (the “Company”) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shares”): Option exercise price per Share: $ Vesting S |
|
| March 3, 2020 |
CFMS / ConforMIS, Inc. S-8 - - S-8 Registration No. 333- As filed with the Securities and Exchange Commission on March 2, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| March 3, 2020 |
CFMS / ConforMIS, Inc. S-8 - - S-8 Registration No. 333- As filed with the Securities and Exchange Commission on March 2, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Conformis, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2463152 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer |
|
| March 3, 2020 |
CONFORMIS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is effective as of February 17, 2020 (the “Effective Date”), by and between Conformis, Inc., a Delaware corporation (the “Company”), and Frederick W. Driscoll, an individual with an address listed on the signature page hereto (the “Consultant”). WHEREAS, the Company desires consulting and similar services relating to |
|
| March 3, 2020 |
Annual Report on Form 10-K for the fiscal year ended December 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Conformis, Inc |
|
| March 3, 2020 |
October 14, 2019 Frederick Driscoll 2 Longbranch Ave Rockport, MA 01966 Re: Offer of employment at Conformis, Inc. |
|
| March 3, 2020 |
CONFORMIS, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of February 17, 2020 (the “Effective Date”) by and between Conformis, Inc., a Delaware corporation (the “Company”), and Robert Howe, an individual residing at 10 Cricket Court, Stow, Massachusetts 01775 (the “Executive”). BACKGROUND A.The Company desires to retain the services of the Execut |
|
| March 3, 2020 |
Form of 2015 Stock Incentive Plan Restricted Stock Grant for Independent Sales Representative Form of Restricted Stock Grant for Independent Sales Representative CONFORMIS, INC. |
|
| March 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| March 3, 2020 |
December 19, 2019 Frederick Driscoll 2 Longbranch Ave Rockport, MA 01966 Re: Extension of Service Period Dear Fred: Thank you for your continuing service to Conformis. |
|
| March 3, 2020 |
Form of Restricted Stock Unit Agreement for Inducement Grants CONFORMIS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Conformis, Inc. (the “Company”) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of Restricted Stock Units (“RSUs”) granted: Vesting Start Date: Vesting Schedule: []% of the RSUs []% of the RSU |
|
| February 14, 2020 |
CFMS / ConforMIS, Inc. / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ConforMIS, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 20717E101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 5, 2020 |
Form of 2020 Incentive Compensation Program Award Letter Form of 2020 Incentive Compensation Program Award Letter PERSONAL & CONFIDENTIAL TO: FROM: DATE: SUBJECT: Conformis, Inc. |
|
| February 5, 2020 |
Conformis Appoints Bob Howe as Chief Financial Officer Conformis Appoints Bob Howe as Chief Financial Officer Also Announces Gary Maingot as SVP, Operations; New Executive Leadership Team Members Contribute Deep Functional Expertise and Technical Knowledge; Inducement Grants Reported BILLERICA, Mass. |
|
| January 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| January 14, 2020 |
Conformis Reports Preliminary Fourth Quarter and Year-End 2019 Revenue Results Conformis Reports Preliminary Fourth Quarter and Year-End 2019 Revenue Results BILLERICA, Mass. |
|
| December 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2019 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 1, 2019 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. |
|
| November 1, 2019 |
CFMS / ConforMIS, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37474 Confo |
|
| November 1, 2019 |
CONFORMIS, INC. PERFORMANCE-VESTED RESTRICTED STOCK AGREEMENT Conformis, Inc. (the “Company”) has selected you to receive the following restricted stock award, which is subject to the provisions of the Company’s 2019 Sales Team Performance-Based Equity Incentive Plan (the “Plan”) and the terms and conditions contained in this Performance-Vested Restricted Stock Agreement. Name of Recipient: Number |
|
| November 1, 2019 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. |
|
| November 1, 2019 |
Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. |
|
| November 1, 2019 |
Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. |
|
| November 1, 2019 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of August 15, 2019, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the Lenders listed on Schedule 1. |
|
| November 1, 2019 |
CONFORMIS, INC. PERFORMANCE-VESTED RESTRICTED STOCK AGREEMENT Conformis, Inc. (the “Company”) has selected you to receive the following restricted stock award, which is subject to the provisions of the Company’s 2015 Stock Incentive Plan (the “Plan”) and the terms and conditions contained in this Performance-Vested Restricted Stock Agreement. Name of Recipient: Number of shares of restricted commo |
|
| November 1, 2019 |
Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2019 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 30, 2019 |
Conformis Reports Third Quarter 2019 Financial Results Conformis Reports Third Quarter 2019 Financial Results BILLERICA, Mass., October 30, 2019 (GLOBE NEWSWIRE) - Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient-specific joint replacement implants designed to fit each patient's unique anatomy, announced today financial results for t |
|
| October 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 Conformis, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-37474 56-2463152 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 15, 2019 |
CFMS / ConforMIS, Inc. / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
